Immuneering Corp — Director's Dealing 2024

Jun 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2024-06-12

Reporting Person: HAUSMAN DIANA (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-12	Stock Option	$1.54	A	33350	Acquired	2034-06-12	Class A Common Stock (33350)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first.